Search form


Press Releases

Axcan Pharma to Present at Scotia Capital Growth Conference in Montreal

Mar 29, 2004 - 12:00 ET

Axcan Pharma to Present at Scotia Capital Growth Conference in Montreal

MONT SAINT-HILAIRE, Quebec--Axcan Pharma Inc. ("Axcan" or the "Company") today announced
that on April 1, 2004, Léon F. Gosselin, President and Chief Executive Officer of the
Company, will make a presentation at the Scotia Capital Growth Conference held in Montreal,
Quebec. This presentation will take place at 9:00 a.m. EST.

Interested parties can access the audio webcast of the presentation on the Company's
website at

Axcan is a leading specialty pharmaceutical company involved in the field of
gastroenterology. The Company markets a broad line of prescription products sold for the
treatment of symptoms in a number of gastrointestinal diseases and disorders such as
inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases and
complications related to cystic fibrosis. Axcan's products are marketed by its own sales
force in North America and Europe. Its common shares are listed on the Toronto Stock
Exchange under the symbol "AXP" and on the NASDAQ National Market under the symbol "AXCA".

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995.
To the extent any statements made in this release contain information that is not
historical, these statements are essentially forward looking and are subject to risks
and uncertainties, including the difficulty of predicting FDA approvals, acceptance and
demand for new pharmaceutical products, the impact of competitive products and pricing,
new product development and launch, reliance on key strategic alliances, availability of
raw materials, the regulatory environment, fluctuations in operating results and other
risks detailed from time to time in the Company's filings with the Securities and
Exchange Commission.

INFORMATION:      David W. Mims
                  Executive Vice President and Chief Operating Officer
                  Axcan Pharma Inc.
                  Tel: (205) 991-8085 ext. 3223